Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.38 |
| ▸ | CCR1 | P32246 | 5/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24358309 | 1.00 | CASP3 (0.38) | CASP3CCR1PIN1MDM4TP53 | |
| SCHEMBL23220747 | 1.00 | CASP3 (0.38) | CASP3CCR1PIN1MDM4TP53 | |
| SCHEMBL24579231 | 0.87 | CASP3 (0.37) | CASP3CCR1MDM4TP53FABP7 | |
| SCHEMBL23056431 | 0.87 | CASP3 (0.38) | CASP3CCR1MDM4TP53FABP7 | |
| SCHEMBL25658636 | 0.87 | CASP3 (0.38) | CASP3CCR1MDM4TP53FABP7 | |
| SCHEMBL25658641 | 0.87 | CASP3 (0.38) | CASP3CCR1MDM4TP53FABP7 | |
| SCHEMBL23056549 | 0.87 | CASP3 (0.38) | CASP3CCR1MDM4TP53FABP7 | |
| SCHEMBL23156917 | 0.87 | CASP3 (0.38) | CASP3CCR1MDM4TP53FABP7 | |
| SCHEMBL23056550 | 0.87 | CASP3 (0.38) | CASP3CCR1MDM4TP53FABP7 | |
| SCHEMBL24580474 | 0.86 | CASP3 (0.37) | CASP3CCR1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125891-A1 | METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE | RNASE1, IRAK1, SERBP1 | CASP3 1588/4885CCR1 2783/4885PIN1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.